Kodiak Sciences Inc (Nasdaq: KOD), a clinical stage biopharmaceutical company specialising in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced yesterday that it has named Taiyin Yang, PhD as a director.
Presently, Dr Yang serves as executive vice president, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc. She joined Gilead in 1993.
Victor Perlroth, MD, chief executive officer of Kodiak Sciences, said, 'Dr Yang joins our board in a growth phase for Kodiak as we pursue our 2022 Vision for KSI-301 in retinal vein occlusion, wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy and our anticipated Biologics License Application (BLA) and supplemental BLA submissions. Dr Yang's deep experience with product development, commercial manufacturing and quality operations will be instrumental as we advance KSI-301 and our deepening pipeline of bi-specific and triplet ABC product candidates.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes